NCT01343498 - Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Malignant Solid Tumour

Interventions

DRUG

BEZ235

BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.

Trial Locations (2)

37203

Tennessee Oncology, Nashville

71304

Oklahoma University, Oklahoma City